American States Water Company vs Quest Diagnostics Inc — how do they compare? American States Water Company trades at $84.54 (market cap $3.33B), while Quest Diagnostics Inc trades at $202.3 (market cap $22.80B). The key difference: Quest Diagnostics Inc is far larger — about 6.8× American States Water Company's market cap, and American States Water Company pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| AWR | DGX | |
|---|---|---|
Market Cap | $3.33B | $22.80B |
Sector | Utilities | Health |
52-Week High | $85.05 | $216.02 |
52-Week Low | $70.10 | $166.42 |
Enterprise Value | $4.24B | $28.82B |
Dividend Yield | 2.37% | 1.67% |
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $85.05, up 0.64% today, with a bullish technical signal from moving averages and strong profitability metrics including a 19.66% net income margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200 million ATM equity offering. The stock shows consistent dividend performance with a 71-year growth streak, though recent quarters saw mixed earnings results versus expectations.
Outlook remains stable with revenue growth to $679 million in 2026 and solid cash flow, but risks include regulatory pressures and interest rate sensitivity. Analysts are cautious with only 20% buy ratings. The stock offers defensive appeal but faces execution risks in a high-valuation environment.
No Aura AI signal available yet.
Trailing returns across standard periods
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →